NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01720108,Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty,https://clinicaltrials.gov/study/NCT01720108,EPCAT II,COMPLETED,In this study the investigators want to look at whether using aspirin instead of rivaroxaban (after initial treatment with rivaroxaban) works as well at preventing blood clots while also reducing risk of bleeding and is more cost effective in patients who have either a total hip replacement or total knee replacement.,NO,Venous Thromboembolism,DRUG: rivaroxaban and ASA,"symptomatic venous thromboembolism, up to 4 years|major or clinically relevant non-major bleeding, up to 4 years","survival, up to 4 years|myocardial infarction, up to 4 years|stroke, up to 4 years|wound infection, up to 4 years|cost-effectiveness, up to 4 years",,David Anderson,Canadian Institutes of Health Research (CIHR),ALL,"ADULT, OLDER_ADULT",PHASE3,3426,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",EPCATII.001,2013-02-24,2016-07,2016-07,2012-11-02,,2018-01-25,"Capital Health, Halifax, Nova Scotia, B3H 3A7, Canada",
